Total Payments
$1.2M
2024 Payments
$187,678
Companies
43
Transactions
2,628
Medicare Patients
10,848
Medicare Billing
$5.8M
Payment Breakdown by Category
Other$929,250 (77.9%)
Travel$144,074 (12.1%)
Consulting$74,384 (6.2%)
Food & Beverage$44,267 (3.7%)
Education$441.75 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $887,142 | 494 | 74.4% |
| Travel and Lodging | $144,074 | 682 | 12.1% |
| Consulting Fee | $74,384 | 28 | 6.2% |
| Food and Beverage | $44,267 | 1,371 | 3.7% |
| Honoraria | $42,108 | 22 | 3.5% |
| Education | $441.75 | 31 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $492,915 | 842 | $0 (2024) |
| PFIZER INC. | $193,763 | 368 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $122,100 | 139 | $0 (2024) |
| Radius Health, Inc. | $79,092 | 113 | $0 (2022) |
| Lilly USA, LLC | $65,990 | 145 | $0 (2022) |
| Celgene Corporation | $53,687 | 164 | $0 (2019) |
| Alexion Pharmaceuticals, Inc. | $37,703 | 63 | $0 (2024) |
| Horizon Therapeutics plc | $30,313 | 81 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $29,678 | 91 | $0 (2022) |
| Aurinia Pharma U.S., Inc. | $23,188 | 42 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $187,678 | 256 | Amgen Inc. ($108,129) |
| 2023 | $105,478 | 175 | Amgen Inc. ($65,827) |
| 2022 | $110,610 | 182 | Amgen Inc. ($35,929) |
| 2021 | $58,201 | 178 | Amgen Inc. ($17,847) |
| 2020 | $71,309 | 136 | Amgen Inc. ($23,860) |
| 2019 | $262,203 | 605 | Amgen Inc. ($106,308) |
| 2018 | $235,523 | 623 | Amgen Inc. ($76,414) |
| 2017 | $161,415 | 473 | Amgen Inc. ($58,602) |
All Payment Transactions
2,628 individual payment records from CMS Open Payments — Page 1 of 106
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $52.05 | General |
| Category: Inflammation | ||||||
| 12/23/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $43.50 | General |
| Category: Inflammation | ||||||
| 12/23/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $33.50 | General |
| Category: Inflammation | ||||||
| 12/23/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | Cash or cash equivalent | $18.52 | General |
| Category: Inflammation | ||||||
| 12/23/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $2.00 | General |
| Category: Inflammation | ||||||
| 12/20/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: Inflammation | ||||||
| 12/20/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: Inflammation | ||||||
| 12/18/2024 | Amgen Inc. | EVENITY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: Bone Health | ||||||
| 12/18/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | In-kind items and services | $175.46 | General |
| Category: Inflammation | ||||||
| 12/17/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $142.26 | General |
| Category: Inflammation | ||||||
| 12/17/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $30.00 | General |
| Category: Inflammation | ||||||
| 12/17/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $6.57 | General |
| Category: Inflammation | ||||||
| 12/16/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,850.00 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/13/2024 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | Cash or cash equivalent | $10.24 | General |
| Category: Bone Health | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $69.39 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Travel and Lodging | In-kind items and services | $11.03 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 11/27/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | In-kind items and services | $454.89 | General |
| Category: Inflammation | ||||||
| 11/21/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: Inflammation | ||||||
| 11/12/2024 | Amgen Inc. | EVENITY (Biological) | Travel and Lodging | Cash or cash equivalent | $49.35 | General |
| Category: Bone Health | ||||||
| 11/12/2024 | Amgen Inc. | EVENITY (Biological) | Travel and Lodging | Cash or cash equivalent | $33.50 | General |
| Category: Bone Health | ||||||
| 11/12/2024 | Amgen Inc. | EVENITY (Biological) | Travel and Lodging | Cash or cash equivalent | $32.85 | General |
| Category: Bone Health | ||||||
| 11/12/2024 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | Cash or cash equivalent | $25.77 | General |
| Category: Bone Health | ||||||
| 11/12/2024 | Amgen Inc. | EVENITY (Biological) | Travel and Lodging | Cash or cash equivalent | $10.00 | General |
| Category: Bone Health | ||||||
| 11/11/2024 | Amgen Inc. | EVENITY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: Bone Health | ||||||
| 11/11/2024 | Amgen Inc. | EVENITY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: Bone Health | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 28 | 1,758 | 34,529 | $1.9M | $676,079 |
| 2021 | 43 | 4,504 | 137,735 | $6.6M | $2.5M |
| 2020 | 48 | 4,586 | 154,324 | $5.6M | $2.6M |
Total Patients
10,848
Total Services
326,588
Medicare Billing
$5.8M
Procedure Codes
119
All Medicare Procedures & Services
119 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 23 | 4,525 | $407,250 | $158,083 | 38.8% |
| J9312 | Injection, rituximab, 10 mg | Office | 2022 | 14 | 1,803 | $315,000 | $122,600 | 38.9% |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | Office | 2022 | 23 | 3,120 | $280,800 | $98,138 | 34.9% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2022 | 24 | 6,100 | $305,000 | $76,756 | 25.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 61 | 3,660 | $111,601 | $59,718 | 53.5% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2022 | 14 | 12,242 | $122,400 | $55,278 | 45.2% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2022 | 12 | 1,110 | $122,100 | $32,253 | 26.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 261 | 276 | $69,000 | $20,740 | 30.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 70 | 142 | $71,000 | $15,767 | 22.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 68 | 69 | $23,460 | $7,229 | 30.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 154 | 159 | $27,825 | $7,025 | 25.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 48 | 98 | $13,110 | $5,473 | 41.7% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 62 | 91 | $15,925 | $3,522 | 22.1% |
| 20553 | Injection of trigger points, 3 or more muscles | Office | 2022 | 47 | 50 | $6,000 | $1,744 | 29.1% |
| 20551 | Injection into tendon at attachment to bone or muscle | Office | 2022 | 37 | 65 | $7,150 | $1,707 | 23.9% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2022 | 44 | 44 | $6,600 | $1,691 | 25.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 156 | 160 | $4,800 | $1,671 | 34.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 21 | 62 | $7,750 | $1,394 | 18.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 158 | 161 | $4,025 | $1,237 | 30.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 67 | 92 | $10,320 | $1,079 | 10.5% |
| 86140 | Measurement c-reactive protein for detection of infection or inflammation | Office | 2022 | 159 | 162 | $2,916 | $830.38 | 28.5% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2022 | 98 | 160 | $3,040 | $608.79 | 20.0% |
| 82306 | Vitamin d-3 level | Office | 2022 | 17 | 17 | $1,615 | $502.90 | 31.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 18 | 33 | $1,155 | $394.23 | 34.1% |
| 86160 | Measurement of complement (immune system proteins), antigen, | Office | 2022 | 16 | 32 | $1,440 | $363.27 | 25.2% |
About Dr. Gary Myerson, MD
Dr. Gary Myerson, MD is a Rheumatology healthcare provider based in Atlanta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1346282399.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gary Myerson, MD has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $187,678 received in 2024. These payments were reported across 2,628 transactions from 43 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($887,142).
As a Medicare-enrolled provider, Myerson has provided services to 10,848 Medicare beneficiaries, totaling 326,588 services with total Medicare billing of $5.8M. Data is available for 3 years (2020–2022), covering 119 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Atlanta, GA
- Active Since 06/12/2006
- Last Updated 11/12/2020
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1346282399
Products in Payments
- EVENITY (Biological) $198,837
- XELJANZ (Drug) $179,396
- Prolia (Biological) $177,092
- SAPHNELO (Biological) $118,120
- Otezla (Drug) $116,448
- Tymlos (Biological) $78,792
- RAYOS (Drug) $42,240
- TALTZ (Drug) $35,211
- COSENTYX (Biological) $29,678
- LUPKYNIS (Drug) $23,188
- BENLYSTA (Biological) $15,700
- Enbrel (Biological) $12,474
- SIMPONI ARIA (Biological) $11,767
- OLUMIANT (Drug) $9,573
- LYRICA (Drug) $7,349
- Actemra (Biological) $3,860
- INFLECTRA (Biological) $3,541
- Uloric (Drug) $2,882
- RINVOQ (Biological) $2,819
- KRYSTEXXA (Biological) $1,246
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Atlanta
William Wilson, Md, MD
Rheumatology — Payments: $398,508
Rheumatology $398,508
Paul Sutej, Md, MD
Rheumatology — Payments: $343,808
Rheumatology $343,808
Sung Lim, M.d., M.p.h, M.D., M.P.H
Rheumatology — Payments: $124,019
Rheumatology $124,019
Dr. John Goldman, Md, MD
Rheumatology — Payments: $102,184
Rheumatology $102,184
Kimberley Wilson, M.d, M.D
Rheumatology — Payments: $41,792
Rheumatology $41,792
Dr. Elizabeth Butler, M.d, M.D
Rheumatology — Payments: $27,214
Rheumatology $27,214